According to Zacks, “Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company’s product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc. is based in La Jolla, CA. “
A number of other brokerages have also weighed in on ARTL. LADENBURG THALM/SH SH assumed coverage on shares of Artelo Biosciences in a research note on Friday, February 12th. They set a “buy” rating and a $7.00 target price for the company. Maxim Group raised shares of Artelo Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, January 7th.
ARTL traded down $0.08 during mid-day trading on Tuesday, reaching $1.29. 614,555 shares of the company traded hands, compared to its average volume of 7,156,317. The stock has a market capitalization of $29.84 million, a P/E ratio of -1.28 and a beta of 2.52. The company’s fifty day moving average price is $1.55 and its 200-day moving average price is $1.16. Artelo Biosciences has a 52-week low of $0.45 and a 52-week high of $3.67.
Artelo Biosciences (NASDAQ:ARTL) last announced its earnings results on Monday, April 12th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.09.
An institutional investor recently bought a new position in Artelo Biosciences stock. LVM Capital Management Ltd. MI bought a new position in Artelo Biosciences, Inc. (NASDAQ:ARTL) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 20,000 shares of the company’s stock, valued at approximately $33,000. LVM Capital Management Ltd. MI owned 0.13% of Artelo Biosciences as of its most recent filing with the SEC.
Artelo Biosciences Company Profile
Artelo Biosciences, Inc is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.
Recommended Story: Short Selling – Explanation For Shorting Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com